-Humanigen: Rises on UK application for rolling review of COVID-19 therapy

Humanigen

14/06/2021 12:04

** Drug developer's shares  HGEN.O  up 1.9% at $21.66
premarket
    ** Co says it has started process of UK authorization for
its drug, lenzilumab, to treat patients hospitalized with
COVID-19, through a rolling review submission (https://refini.tv/3iIy03U)
    ** Application supported by late-stage trial data that show
lenzilumab improved chances of survival without ventilation in
newly hospitalized COVID-19 patients - HGEN
    ** Rolling reviews speed up approval process by allowing
researchers to submit their findings in real-time, even before
final trial data is ready
    ** Last month, HGEN submitted emergency use authorization
application to U.S. FDA for lenzilumab  urn:newsml:reuters.com:*:nL3N2NF38I
    ** Stock up ~21% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))